Table 4 Results of enhanced MRI combined with tumour markers
| Â | Â | Clinical pathological | Â | Â | ||
|---|---|---|---|---|---|---|
| Â | Metastasis | Non-metastasis | Kappa | P | ||
CEA | Parallel | Metastasis | 165 (98.80%) | 97 (58.08%) | 0.318 | <0.001 |
Non-metastasis | 2 (0.20%) | 70 (41.92%) | Â | Â | ||
Serial | Metastasis | 114 (68.26%) | 9 (5.39%) | 0.629 | <0.001 | |
Non-metastasis | 53 (31.74%) | 158 (94.61%) | Â | Â | ||
CA19-9 | Parallel | Metastasis | 152 (91.02%) | 101 (59.88%) | 0.305 | <0.001 |
Non-metastasis | 15 (8.98%) | 66 (40.12%) | Â | Â | ||
Serial | Metastasis | 80 (47.90%) | 13 (7.78%) | 0.401 | <0.001 | |
Non-metastasis | 87 (52.10%) | 154 (92.22%) | Â | Â | ||
CA125 | Parallel | Metastasis | 148 (88.62%) | 110 (65.87%) | 0.228 | <0.001 |
Non-metastasis | 19 (11.38%) | 57 (34.13%) | Â | Â | ||
Serial | Metastasis | 46 (27.54%) | 21 (12.57%) | 0.150 | 0.001 | |
Non-metastasis | 121 (72.46%) | 146 (87.43%) | Â | Â | ||
CA72-4 | Parallel | Metastasis | 156 (93.41%) | 136 (81.44%) | 0.162 | <0.001 |
Non-metastasis | 11 (6.59%) | 41 (18.56%) | Â | Â | ||
Serial | Metastasis | 100 (59.88%) | 14 (8.38%) | 0.515 | <0.001 | |
Non-metastasis | 67 (40.12%) | 153 (91.62%) | Â | Â | ||